This inverse relationship between adverse cardiovascular outcomes and BChE levels suggests determination of BChE activity in plasma as a risk factor and prognostic biomarker in CAD (Sulzgruber et al., 2015). The gene discussed is BCHE; the disease is coronary artery disorder.